Shut Down

Mindstrong Stock

Digital Mental Healthcare

Sign up today and learn more about Mindstrong Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

General Catalyst Partners


Mountain View CA, US

Total Funding


About Mindstrong Stock

Mindstrong's patented science and technology was developed by Dr. Dagum, and is based on four years of extensive clinical studies applying machine intelligence to human-computer interactions patterns. Dr. Dagum's work creates, for the first time, a way to objectively and continuously measure brain function day-to-day providing new insight not previously possible with traditional neuropsychological and imaging techniques. Mindstrong products are in clinical trials in numerous partnership projects with payers, providers, academics and the pharmaceutical industry to bring these new tools to bear on answering the most fundamental questions in behavioral health.


Funding History

June 2017$14.0M
June 2018$15.0M
December 2018$31.0M
May 2020$100M


Chief Executive Officer

Michelle Wagner

Chief Technology Officer

Miguel Alvarado


healthtechpulse - Jun, 9 2020

COVID-19 accelerates healthtech adoption

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: